BioSpace News Archive

Florida Cancer Specialists & Research Institute, LLC (FCS) medical oncologist and hematologist Ernesto Bustinza-Linares, MD is co-author of a recent abstract published in the American Society of Clinical Oncology Journal, JCO Precision Oncology, that uncovers a new testing method to determine personalized care options for patients with metastatic non-small cell lung cancer (NSCLC).

Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible, “Median” or the “Company”) today reported its 2023 consolidated annual financial results, as of December 31, 2023, and provided financial information (unaudited) for the first quarter of 2024, as of March 31, 2024.

VILYA, Inc. announced the publication of a new study in Science that validates the company’s foundational drug discovery approach.

Efforts by the ACC, the AHA, the HFSA, the Heart Rhythm Society and The Society for Cardiovascular Angiography & Interventions to create a new, independent Board of Cardiovascular Medicine under the ABMS are closer to becoming a reality with the creation of a formal Board of Directors and the announcement by the ABMS Advisory Board on Specialty Board Development of an open comment period.

Synedgen, Inc. announced it has completed IND-enabling studies for its lead candidate, MIIST305.

Medical device innovator and worldwide leader in minimally invasive neurosurgery NICO Corporation is launching its latest product innovation at next week’s American Association of Neurosurgical Surgeons Annual Scientific Meeting in Chicago, Booth #825.

German-based joimax® is excited to announce the full registration of all its products for India, one of the fastest growing endoscopic spine surgery markets worldwide.

Y-mAbs Therapeutics, Inc. announced the acceptance of four abstracts at the 2024 American Society of Clinical Oncology Annual Meeting, taking place May 31 – June 4, 2024 in Chicago, IL.

NKGen Biotech, Inc. announced the details disclosed in today’s presentation by Paul Y. Song, MD, Chairman and Chief Executive Officer of NKGen, entitled “Evaluating Adoptive Cellular Immunotherapy for Neurodegeneration with Autologous SNK01”.

ResMed Inc. announced results for its quarter ended March 31, 2024.